DrugPatentWatch Database Preview
Alendronate sodium - Generic Drug Details
What are the generic sources for alendronate sodium and what is the scope of alendronate sodium patent protection?
Alendronate sodium
is the generic ingredient in four branded drugs marketed by West-ward Pharms Int, Merck, Mission Pharma, Apotex, Aurobindo Pharma, Cipla Ltd, Hangzhou Binjiang, Impax Labs Inc, Jubilant Cadista, Mylan, Neopharma, Sun Pharma Global, Teva Pharms, Upsher-smith Labs, Watson Labs, and Merck And Co Inc, and is included in eighteen NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.There are twenty-five drug master file entries for alendronate sodium. Twenty-eight suppliers are listed for this compound.
Summary for alendronate sodium
| US Patents: | 5 |
| Tradenames: | 4 |
| Applicants: | 16 |
| NDAs: | 18 |
| Drug Master File Entries: | 25 |
| Suppliers / Packagers: | 28 |
| Bulk Api Vendors: | 150 |
| Clinical Trials: | 24 |
| Patent Applications: | 7,765 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for alendronate sodium |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for alendronate sodium |
| DailyMed Link: | alendronate sodium at DailyMed |
Pharmacology for alendronate sodium
| Ingredient-type | Diphosphonates |
| Drug Class | Bisphosphonate |
Medical Subject Heading (MeSH) Categories for alendronate sodium
Synonyms for alendronate sodium
| (4-amino-1-hydroxy-1-phosphono-butyl)phosphonic acid |
| (4-AMINO-1-HYDROXY-1-PHOSPHONOBUTYL)PHOSPHONIC ACI |
| (4-amino-1-hydroxy-1-phosphonobutyl)phosphonic acid |
| (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonic Acid Monosodium Salt |
| (4-amino-1-hydroxybutane-1,1-diyl)bis(phosphonic acid) |
| (4-amino-1-hydroxybutane-1,1-diyl)bisphosphonic acid |
| (4-Amino-1-hydroxybutane-1,1-diyl)diphosphonic acid |
| (4-Amino-1-Hydroxybutylidene)-Bisphosphonic Acid |
| (4-Amino-1-hydroxybutylidene)bisphosphonic acid |
| (4-Amino-1-hydroxybutylidene)bisphosphonic acid monosodium salt |
| (4-Amino-1-hydroxybutylidene)diphosphonic acid |
| (4-azanyl-1-oxidanyl-1-phosphono-butyl)phosphonic acid |
| 121268-17-5 (mono-hydrochloride salt, trihydrate) |
| 129318-43-0 |
| 1yhm |
| 376A361 |
| 4-AMINO-1-HYDROXY-1-PHOSPHONOBUTYL PHOSPHONIC ACID,MONOSODIUM |
| 4-Amino-1-hydroxy-1,1-butylidinediphosphonic acid |
| 4-Amino-1-hydroxybutane-1,1-diphosphonate |
| 4-Amino-1-hydroxybutane-1,1-diphosphonic Acid |
| 4-AMINO-1-HYDROXYBUTANE-1,1-DIYLDIPHOSPHONATE |
| 4-Amino-1-hydroxybutylidene-1,1-bis(phosphonic acid) |
| 4-Amino-1-hydroxybutylidene-1,1-bisphosphonate |
| 4-AMINO-1-HYDROXYBUTYLIDENE-1,1-BISPHOSPHONIC ACID MONOSODIUM SALT |
| 4-amino-1-hydroxybutylidene-bisphosphonic acid |
| 4-Amino-1-hydroxybutylidine-1,1-bisphosphonate |
| 4-amino-1,1-diphosphonobutan-1-ol |
| 4988K7X26P |
| 66376-36-1 |
| 68549-EP2270008A1 |
| 68549-EP2292617A1 |
| 68549-EP2295426A1 |
| 68549-EP2295427A1 |
| 68549-EP2308855A1 |
| 70013-EP2292592A1 |
| 70013-EP2295409A1 |
| 70013-EP2305640A2 |
| 70013-EP2308479A2 |
| A805927 |
| A835441 |
| AB0008472 |
| AB01274863-01 |
| AB10152 |
| ABDP |
| AC1L1CW3 |
| AC1Q1W16 |
| Acide alendronique |
| Acide alendronique [INN-French] |
| Acido alendronico |
| Acido alendronico [INN-Spanish] |
| Acidum alendronicum |
| Acidum alendronicum [INN-Latin] |
| AHBuBP |
| AHButBP |
| AHD |
| AJ-74282 |
| AK117216 |
| AKOS001015793 |
| AKOS015895071 |
| Alend |
| alendronate |
| Alendronate acid |
| Alendronate sodium anhydrous |
| Alendronate, Sodium Salt |
| Alendronate, Sodium, Trihydrate |
| ALENDRONIC ACID |
| Alendronic acid (INN) |
| Alendronic acid [INN:BAN] |
| Alendronic Acid Monosodium Salt |
| Alendronic acid sodium salt |
| ALENDRONIC ACID, SODIUM |
| Alendronic acid, Sodium aldendronate |
| Alendronicacid |
| Almerol |
| Aminohydroxybutane Bisphosphonate |
| AN-32438 |
| AN-38504 |
| ANW-43156 |
| API0001401 |
| API0005892 |
| Arendal |
| AS-10963 |
| Avalent |
| AX8002169 |
| BB_SC-02791 |
| BB_SC-2791 |
| BDBM25313 |
| BG0020 |
| BIDD:GT0180 |
| Binosto |
| bisphosphonate |
| bisphosphonate, 65 |
| Bonalon |
| BPH 1 |
| BRD-K75527158-323-01-3 |
| C-15277 |
| C07752 |
| C4H12NNaO7P2 |
| C4H13NO7P2 |
| CAKRAHQRJGUPIG-UHFFFAOYSA-M |
| CC-00619 |
| CCG-220631 |
| CHEBI:2567 |
| CHEMBL675 |
| CHEMBL870 |
| CTK8B3779 |
| D07119 |
| D09KLR |
| DB00630 |
| DTXSID5022568 |
| EX-101 |
| Fosamac |
| Fosamax |
| Fosamax (TN) |
| FT-0641064 |
| G-704650 |
| GTH-42 |
| GTH-42J |
| GTH-42V |
| GTH-42W |
| GTPL3141 |
| HMS3604I12 |
| HSCI1_000337 |
| HSDB 7990 |
| Hydrogen (4-amino-1-hydroxy-1-phosphonobutyl)phosphonate (Na+) |
| I04-9842 |
| I06-0478 |
| Indrol |
| J-005667 |
| J10298 |
| KS-1028 |
| L-670452 |
| LS-106421 |
| LS-106423 |
| M-1609 |
| MER-103 |
| MFCD00868112 |
| MFCD01861681 |
| MK 217 |
| MK-0217 |
| MK-217 |
| Monosodium (4-Amino-1-hydroxy-1-phosphonobutyl)phosphonate |
| Monosodium alendronate |
| NCGC00096054-01 |
| NCGC00096054-03 |
| NCGC00096054-04 |
| NeoBon |
| OGSPWJRAVKPPFI-UHFFFAOYSA-N |
| Onclast |
| Oprea1_422906 |
| OR006545 |
| Osteovan |
| P,P'-(4-Amino-1-hydroxybutylidene)bis-phosphonic acid monosodium salt |
| P,P'-(4-Amino-1-hydroxybutylidene)bisphosphonic acid |
| PHOSPHONATE, (4-AMINO-1-HYDROXY-1-PHOSPHONOBUTYL)-, SODIUM SALT |
| Phosphonic acid, (4-amino-1-hydroxybutylidene)bis |
| Phosphonic acid, (4-amino-1-hydroxybutylidene)bis- |
| Phosphonic acid, (4-amino-1-hydroxybutylidene)bis-, monosodium salt |
| Q-200607 |
| SBI-0206778.P001 |
| SC-17297 |
| SC-22170 |
| SCHEMBL18898 |
| SCHEMBL328770 |
| sodium (4-amino-1-hydroxy-1-phosphono-butyl)-hydroxy-phosphinate |
| sodium (4-amino-1-hydroxy-1-phosphonobutyl)-hydroxyphosphinate |
| sodium (4-azanyl-1-oxidanyl-1-phosphono-butyl)-oxidanyl-phosphinate |
| SODIUM ALDENDRONATE |
| Sodium alendronate |
| sodium alendronate(1-) |
| sodium hydrogen(4-amino-1-hydroxy-1-phosphonobutyl)phosphonate |
| SPECTRUM1505166 |
| ST24034598 |
| ST50036159 |
| Steovess |
| Teiroc |
| UNII-4988K7X26P |
| UNII-X1J18R4W8P |
| VZ20111 |
| X1J18R4W8P |
| Y-8756 |
| Z56771118 |
| ZINC3801919 |
US Patents and Regulatory Information for alendronate sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Upsher-smith Labs | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 075871-003 | Apr 22, 2009 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Hangzhou Binjiang | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 090258-003 | Sep 24, 2009 | AB | RX | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | |||
| Upsher-smith Labs | ALENDRONATE SODIUM | alendronate sodium | TABLET;ORAL | 075871-005 | Apr 22, 2009 | DISCN | No | No | ➤ Try a Free Trial | ➤ Try a Free Trial | ➤ Try a Free Trial | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for alendronate sodium
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Merck And Co Inc | FOSAMAX | alendronate sodium | TABLET;ORAL | 020560-002 | Sep 29, 1995 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Merck And Co Inc | FOSAMAX | alendronate sodium | TABLET;ORAL | 020560-001 | Sep 29, 1995 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Merck And Co Inc | FOSAMAX | alendronate sodium | TABLET;ORAL | 020560-003 | Apr 25, 1997 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for alendronate sodium
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2004035004 | ➤ Try a Free Trial |
| Slovakia | 932000 | ➤ Try a Free Trial |
| Poland | 338635 | ➤ Try a Free Trial |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for alendronate sodium
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2006002,C0998292 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824 |
| 2006002 | Lithuania | ➤ Try a Free Trial | PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824 |
| 2007 00045 | Denmark | ➤ Try a Free Trial | PRODUCT NAME: ALENDRONSYRE, NATRIUMTRIHYDRAT, OG COLECALCIFEROL |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: